BioSpace

EyePoint will halve workforce, end pivotal wet AMD trials early following second fail

EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shifting attention to the asset’s potential in diabetic macular edema.

By BioSpace

1 min read
EyePoint will halve workforce, end pivotal wet AMD trials early following second fail
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights